MDACC Study No:2012-0669 ( NCT No: NCT01746836)
Title:Ponatinib as Second Line Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib, Dasatinib or Nilotinib
Principal Investigator:Jorge Cortes
Treatment Agent:Ponatinib
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if ponatinib can help to
control CML in chronic phase. The safety of this drug will also be studied.

Ponatinib is designed to block the function of BCR-ABL, which is the abnormal
protein responsible for causing CML. This may cause the cancer cells to die.

Ponatinib may cause a blood clot to form in an artery or in a vein. Depending
on the location of the clot, this could cause a heart attack, a stroke, severe
damage to other tissue, or death. A blood clot may occur within 2 weeks after
you start taking the drug. About 25% (1 in 4) of patients taking the drug form
an abnormal clot. Blood clots can occur in patients that do not have other
known risk factors for forming clots. If you develop a blood clot, you will
need to stop taking ponatinib. In some cases, emergency surgery could be needed
to remove the clot and restore blood flow.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Ponatinib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Ariad Pharmaceuticals
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults